Federal health subsidies barred from covering gender transition care
S. 977 — End Taxpayer Funding of Gender Experimentation Act of 2025 · Filed by Roger Marshall (R-KS) · 14 cosponsors · Introduced Mar 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits federal funds from paying for gender transition procedures and bars health insurance plans that cover such procedures from receiving federal subsidies under the Affordable Care Act. It defines gender transition procedures broadly to include hormonal treatments, surgeries, and cosmetic procedures, with narrow exceptions for intersex conditions and emergency medical care. States and individuals may still purchase separate coverage with non-federal money, but federal tax credits and employer health insurance subsidies cannot support plans that include gender transition coverage.
Why we flagged it
The bill's operative mechanism is to exclude a category of health care from federal insurance subsidies. While framed as a taxpayer-funding prohibition, the substantive effect is a coverage restriction within federally supported insurance markets, not a simple spending ban.
What the text implies
- The definition of 'gender transition procedure' includes cosmetic and aesthetic surgeries (facial feminization, breast implants, liposuction, hair reconstruction, voice surgery) that may be sought for reasons unrelated to gender identity, creating ambiguity in enforcement and potential over-reach.
- Section 306 carves out treatment of 'complications' from gender transition procedures, but the bill does not define what constitutes a complication or how physicians should document causation, creating potential litigation and administrative burden.
- The exclusion for intersex conditions (Section 307(3)(B)(i)-(ii)) requires 'medically verifiable disorder of sex development' or genetic/biochemical testing, potentially excluding individuals with ambiguous sex characteristics who lack access to such testing or whose conditions fall outside narrow diagnostic criteria.
- By disallowing ACA premium credits and employer health insurance tax credits for plans covering gender transition procedures, the bill may fragment insurance markets and increase administrative costs for insurers managing separate coverage tiers.
- The bill's effective date (1 year after enactment for ACA credits, plan years thereafter) creates a transition period during which existing plans must be restructured, potentially destabilizing coverage for individuals currently enrolled.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill restricts access to a category of health care within federally subsidized insurance markets, preventing individuals who receive ACA credits or work for employers claiming health insurance tax credits from obtaining plans that cover gender transition procedures—even if they would otherwise choose such coverage. While non-federal separate purchase remains legal, the practical effect is to narrow the scope of federally supported health insurance options available to citizens.
Named in the bill
Internal Revenue Service, Centers for Medicare & Medicaid Services, Department of Health and Human Services, Affordable Care Act, ACA exchanges, Health insurance issuers, Employers offering health insurance
Where it stands
14 cosponsors: 14 Republicans.
- Mar 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Mar 12, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
4 lobbying clients named this bill on 13 disclosure filings across 7 quarters, Mar 2025 to Sep 2026. Those filings disclosed $1,439,519 in lobbying spend. A filing names 45 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 66% of bills with at least one filing.
Roger Marshall, the sponsor, reported $1,921,991 in PAC receipts in the 2026 cycle.
- Human Rights Campaign — $1,371,519 on 7 filings
- American Principles Project — $40,000 on 3 filings
- Alliance Defending Freedom — $20,000 on 1 filing
- Family Research Council — $8,000 on 2 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (12,694 characters) on Nov 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
“Federal health subsidies barred from covering gender transition care” QuorumCivic. https://share.quorumcivic.app/bill/119/s977 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.